Financial Data and Key Metrics Changes - Total revenues for Q3 2022 were $19.5 million, down from $22 million in Q3 2021, reflecting a decrease of approximately 23% [6][27] - Gross margin for the quarter was 10.3%, significantly impacted by inventory write-downs; excluding these, the gross margin would have been 34.4%, compared to 40.4% in Q3 2021 [14][15] - Operating loss for Q3 2022 was $7.1 million, compared to an operating profit of $2.8 million in Q3 2021 [27] - Net loss after tax was $8.9 million in Q3 2022, compared to a profit of $1.3 million in Q3 2021 [31][32] Business Line Data and Key Metrics Changes - Excluding COVID-focused PCR products, revenues for Q3 2022 were $19.2 million, a 2% increase year-over-year and a 6% increase sequentially [39] - The haemoglobins and Fitzgerald businesses contributed to a strong year-over-year revenue increase of 30% [40] - Autoimmune products saw a 20% quarter-over-quarter growth due to optimized capacity and pricing changes [41] Market Data and Key Metrics Changes - Strong demand for haemoglobin products was noted in Asia-Pacific with over 50% year-over-year revenue growth and over 40% in Latin America [42] - Preliminary estimates for Q4 indicate continued growth momentum in haemoglobin instrument placements and improving global HIV test demand [44] Company Strategy and Development Direction - The company is focusing on streamlining its product portfolio by eliminating loss-making legacy products and consolidating production facilities [53] - A new flagship diabetes HbA1c instrument, the Premier 9210, is expected to launch in Q3 next year, aimed at improving gross margins [46][48] - The company is also pursuing partnerships to leverage its lateral flow biological development capabilities and enhance its distribution channels [51][52] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by rising input prices and the need for strategic price adjustments [18][89] - The company expects to end the year with a run rate of around $75 million, with initiatives in place to improve revenue in early 2023 [44][79] - Management expressed confidence in the growth potential of the haemoglobins business, particularly in high-growth markets [58] Other Important Information - The company recorded significant excess and obsolescence charges related to inventory totaling $4.7 million, impacting financial results [7][11] - Impairment charges of $2.3 million were recorded, primarily related to the autoimmune smart reader project and Tri-stat inventory [23][25] Q&A Session Summary Question: What is the expected number of Premier Instruments on the market by 2024? - Management indicated that they expect to have at least three versions of the Premier systems on the market by 2024, focusing on high-growth markets [67][69] Question: Is there enough capacity in Jamestown for continued consolidation? - Management confirmed that the Jamestown site is flexible and will not be closing the Buffalo site, as they are expanding autoimmune manufacturing capabilities [71][72] Question: Any updates on refinancing the remaining portion of the debt? - Management is examining options for refinancing as part of a strategic transaction, with no immediate critical need [75][78] Question: Guidance on gross margin going forward? - Management refrained from providing specific guidance due to various moving pieces but targeted a gross margin level of 40%-45% over the next two to three years [88][89] Question: How did the lab in Buffalo perform this quarter, particularly the Sjogren's test? - The Sjogren's test has shown significant growth, with revenues around $3.5 million, and management sees potential for further scaling [100][108]

Company Overview - Trinity Biotech is a global IVD company providing centralized diagnostic products, lateral flow products, and lab-based testing services[5] - The company has a diversified global platform in Diabetes & Autoimmune markets, as well as Point of Care & Home Testing spaces[6] - Trinity Biotech has core competencies in product development, lab services, regulatory processes, manufacturing & supply chain[6] Financial Performance & Projections - FY21 revenue was $93 million, with $72 million excluding COVID-related revenues[6] - The company projects double-digit growth between 2023-2025 and aims to double recurring revenue by 2025[6] - In H1/2022, Premier 9210 (HbA1c Lab) accounted for approximately 30% of revenues[46] - The company is targeting >20% revenue growth in 2024-2025 with a 45% gross margin[79] - The company is targeting an adjusted operating margin of 15%-20%+ by 2025[79] Market & Growth Strategies - The global Point of Care market is projected to reach $50 billion by 2025[37] - The company is targeting 25% of the 180 million tests/year market in Africa with its WHO-approved HIV screening test[43] - The company plans to reposition its PoC platform to high-margin growth strategies[63]

Financial Data and Key Metrics Changes - Total revenues for Q2 2022 were $18.5 million, down from $25.8 million in Q2 2021, reflecting a significant decline [22] - Gross margin decreased to 35.3% from 42.7% in Q2 2021, primarily due to reduced demand for COVID-related products [23] - Operating loss for Q2 2022 was $1.4 million compared to an operating profit of $200,000 in Q2 2021 [27] - Net financial expenses increased to $8.3 million in Q2 2022 from $0.3 million in Q2 2021, largely due to early repayment penalties and higher interest rates [28] Business Line Data and Key Metrics Changes - Excluding COVID-related products, revenues for Q2 2022 were approximately $18 million, flat compared to Q2 2021, but up 7% from Q1 2022 [38] - The diabetes A1c product line saw a year-over-year revenue increase of over 25% [38] - Fitzgerald Life Science business experienced a 25% quarter-over-quarter growth [39] Market Data and Key Metrics Changes - Preliminary estimates for Q3 2022 revenues are expected to be between $19 million to $20 million, driven by double-digit year-over-year increases in hemoglobins and Fitzgerald Life Science businesses [39] - HIV point-of-care revenue is anticipated to grow over 30% on a quarter-over-quarter basis due to increased orders from Africa [40] Company Strategy and Development Direction - The company aims to establish a clear vision and strategy focusing on scaling core businesses, particularly in point-of-care and lab services [15] - There is a renewed focus on inorganic growth through partnerships and M&A to scale operations [17] - The company plans to leverage its Fitzgerald brand and optimize its hemoglobins business for profitability [15][47] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the fluid situation regarding COVID-19 and its impact on product sales, particularly PCR testing [60][61] - The company is not relying on COVID-related products as a driver of future strategy [60] - Management is optimistic about growth potential in the autoimmune business and plans to invest significantly in the decentralized testing market [49][52] Other Important Information - The company received a $45.2 million investment from MiCo Group, which includes equity and a convertible note [44] - An early repayment of $35 million of the term loan is expected to save $5 million in annual cash interest expenses [45] - The company is undertaking a portfolio-wide capital and talent allocation review to maximize returns [55] Q&A Session Summary Question: What is the outlook for sales of COVID-related products? - Management indicated that sales have significantly declined and are not expected to be a major part of future strategy [60][61] Question: How should interest expenses be viewed for the upcoming quarters? - Interest on the Perceptive debt is approximately 14%, with expected cash interest costs based on the remaining balance [68] Question: What is the expected share count for the third quarter? - The share count is expected to increase due to shares issued to MiCo being outstanding for a longer period [69] Question: What is the market size for the new variant instrument? - The market for the variant product is expected to generate over $5 million to $6 million in revenue annually, primarily in the U.S. [84] Question: What is the company's strategy regarding potential partnerships? - The company is exploring partnerships with both younger tech companies and traditional CPG companies to enhance its market position [94][96]

[Company Overview and Q1 2022 Highlights](index=1&type=section&id=Company%20Overview%20and%20Q1%202022%20Highlights) Trinity Biotech plc announced its Q1 2022 financial results, highlighting strategic refinancing and investment to strengthen capital structure and pursue growth opportunities [Introduction and Announcement](index=1&type=section&id=1.1%20Introduction%20and%20Announcement) Trinity Biotech plc, a diagnostic product developer and manufacturer, released its Q1 2022 financial results - Trinity Biotech plc announced its Q1 2022 financial results[2](index=2&type=chunk) [CEO Commentary and Strategic Outlook](index=4&type=section&id=1.2%20CEO%20Commentary%20and%20Strategic%20Outlook) CEO Ronan O'Caoimh highlighted successful Q1 2022 refinancing with Perceptive Advisors and a strategic investment from MiCo Group, enhancing capital structure for future growth - The CEO highlighted successful Q1 2022 refinancing with Perceptive Advisors and a **$45 million strategic investment** from MiCo Group in May 2022[19](index=19&type=chunk) - These transactions are expected to strengthen Trinity Biotech's capital structure, facilitate refinancing of remaining Perceptive Advisor debt, and position the company to capture growth opportunities in the evolving diagnostics landscape[19](index=19&type=chunk) [Q1 2022 Financial Results Analysis](index=1&type=section&id=Q1%202022%20Financial%20Results%20Analysis) Q1 2022 saw a significant revenue decline, reduced profitability due to lower gross margins, increased financial expenses, and a substantial net loss [Revenue Performance](index=1&type=section&id=2.1%20Revenue%20Performance) Total revenue in Q1 2022 significantly decreased by 26.6% year-over-year, primarily driven by a substantial decline in clinical laboratory revenue, partially offset by modest growth in point-of-care revenue [Total Revenue](index=1&type=section&id=2.1.1%20Total%20Revenue) Total revenue for Q1 2022 was $18.8 million, a 26.6% decrease from $25.6 million in Q1 2021 | Metric | Q1 2021 (US$'000) | Q1 2022 (US$'000) | Change (%) | | :---------------- | :--------------- | :--------------- | :--------- | | Total Revenues | 25,594 | 18,776 | (26.6)% | [Segmental Revenue (Point-of-Care, Clinical Laboratory)](index=1&type=section&id=2.1.2%20Segmental%20Revenue%20(Point-of-Care,%20Clinical%20Laboratory)) Point-of-Care revenue increased by 14.6% to $2.2 million, driven by higher HIV test kit sales in Africa, while Clinical Laboratory revenue decreased by 29.9% to $16.6 million due to reduced COVID-19 PCR VTM product sales | Segment | Q1 2021 (US$'000) | Q1 2022 (US$'000) | Change (%) | | :---------------- | :--------------- | :--------------- | :--------- | | Point-of-Care | 1,888 | 2,164 | 14.6% | | Clinical Laboratory | 23,706 | 16,612 | (29.9)% | - Point-of-Care revenue growth was primarily attributed to increased sales of HIV test kits in Africa, a market characterized by irregular customer order patterns[3](index=3&type=chunk) - The decline in Clinical Laboratory revenue was mainly due to reduced revenue from COVID-19 related PCR VTM products, resulting from a significant reduction in COVID-19 PCR testing programs and lower unit selling prices for PCR VTM products due to increased global manufacturing capacity[4](index=4&type=chunk) [Profitability](index=1&type=section&id=2.2%20Profitability) Gross profit and margin declined due to sales mix changes and PCR VTM product price pressure, leading to a significant reduction in operating profit and a reported after-tax loss [Gross Profit and Margin](index=1&type=section&id=2.2.1%20Gross%20Profit%20and%20Margin) Gross profit decreased to $7.3 million in Q1 2022 from $10.9 million in Q1 2021, with gross margin declining by 3.9% to 38.7%, primarily due to changes in sales mix and downward price pressure on PCR VTM products | Metric | Q1 2021 (US$'000) | Q1 2022 (US$'000) | Change (US$'000) | Change (%) | | :---------------- | :--------------- | :--------------- | :--------------- | :--------- | | Gross profit | 10,913 | 7,270 | (3,643) | (33.4)% | | Gross margin % | 42.6% | 38.7% | - | (3.9)% | - The decline in gross margin was primarily due to changes in sales mix and downward price pressure on PCR VTM products[5](index=5&type=chunk) [Operating Profit](index=2&type=section&id=2.2.2%20Operating%20Profit) Operating profit significantly decreased to $0.2 million in Q1 2022 from $3.1 million in Q1 2021, mainly due to reduced revenue and gross profit, partially offset by lower overheads | Metric | Q1 2021 (US$'000) | Q1 2022 (US$'000) | Change (US$'000) | | :---------------- | :--------------- | :--------------- | :--------------- | | Operating profit | 3,078 | 173 | (2,905) | - The decrease in operating profit was attributed to reduced revenue and gross profit, partially offset by lower overheads[7](index=7&type=chunk) [Net Loss and EPS](index=2&type=section&id=2.2.3%20Net%20Loss%20and%20EPS) The company reported a Q1 2022 after-tax loss of $12.3 million, a significant decline from a $1.6 million profit in Q1 2021, driven by reduced gross profit, increased financial expenses, and a substantial one-off accounting charge | Metric | Q1 2021 (US$'000) | Q1 2022 (US$'000) | Change (US$'000) | | :--------------------------------------- | :--------------- | :--------------- | :--------------- | | (Loss)/Profit after tax | 1,602 | (12,279) | (13,881) | | Basic (Loss)/Earnings per ADS (US cents) | 7.7 | (50.0) | (57.7) | | Diluted (Loss)/Earnings per ADS (US cents) | 7.1 | (50.0) | (57.1) | - The loss was primarily due to reduced gross profit, increased financial expenses, and a **$10.3 million** one-off accounting charge, including a **$9.7 million** loss on the disposal of exchangeable notes and **$0.6 million** in professional fees related to refinancing[9](index=9&type=chunk)[10](index=10&type=chunk) [Expenses](index=1&type=section&id=2.3%20Expenses) R&D expenses decreased due to cost control, SG&A expenses remained stable, while financial expenses significantly increased due to higher interest rates from debt refinancing [Research & Development Expenses](index=1&type=section&id=2.3.1%20Research%20%26%20Development%20Expenses) R&D expenses decreased to $1.0 million in Q1 2022 from $1.4 million in Q1 2021, reflecting the company's focus on cost control measures | Metric | Q1 2021 (US$'000) | Q1 2022 (US$'000) | Change (US$'000) | Change (%) | | :-------------------------------- | :--------------- | :--------------- | :--------------- | :--------- | | Research & development expenses | 1,437 | 965 | (472) | (32.8)% | - The decrease in R&D expenses was due to a continued focus on cost control measures[6](index=6&type=chunk) [Selling, General & Administrative Expenses](index=1&type=section&id=2.3.2%20Selling,%20General%20%26%20Administrative%20Expenses) Selling, General & Administrative (SG&A) expenses remained largely stable at $5.9 million in Q1 2022, a slight decrease of $0.1 million from Q1 2021 | Metric | Q1 2021 (US$'000) | Q1 2022 (US$'000) | Change (US$'000) | Change (%) | | :-------------------------------- | :--------------- | :--------------- | :--------------- | :--------- | | Selling, general and administrative expenses | 6,019 | 5,936 | (83) | (1.4)% | [Financial Expenses](index=2&type=section&id=2.3.3%20Financial%20Expenses) Financial expenses significantly increased to $2.2 million in Q1 2022 from $1.2 million in Q1 2021, primarily due to debt refinancing in late January 2022, which replaced 4.0% exchangeable notes with a 12.25% senior secured term loan | Metric | Q1 2021 (US$'000) | Q1 2022 (US$'000) | Change (US$'000) | Change (%) | | :---------------- | :--------------- | :--------------- | :--------------- | :--------- | | Financial expenses | 1,210 | 2,244 | 1,034 | 85.5% | - The increase in financial expenses was due to debt refinancing, replacing 4.0% exchangeable notes with a 12.25% senior secured term loan[8](index=8&type=chunk) [Non-IFRS Financial Measures](index=3&type=section&id=2.4%20Non-IFRS%20Financial%20Measures) Adjusted EBITDA was $0.9 million and Adjusted EBITDASO was $1.1 million in Q1 2022, serving as non-IFRS metrics for internal operational management and additional investor analysis | Metric | Q1 2022 (US$m) | | :-------------------- | :----------- | | Adjusted EBITDA | 0.9 | | Adjusted EBITDASO | 1.1 | - Non-IFRS measures (Adjusted EBITDA, Adjusted EBITDASO) are used for internal evaluation and management of company operations, and to assist investors with additional financial analysis[18](index=18&type=chunk) [Capital Structure and Liquidity](index=2&type=section&id=Capital%20Structure%20and%20Liquidity) The company underwent significant debt refinancing in Q1 2022, redeeming exchangeable notes with a new senior secured term loan and equity issuance, impacting its cash balance and overall liquidity [Debt Refinancing and Exchangeable Notes Retirement](index=2&type=section&id=3.1%20Debt%20Refinancing%20and%20Exchangeable%20Notes%20Retirement) In Q1 2022, Trinity Biotech redeemed approximately $99.7 million of exchangeable notes, funded by a new term loan, existing cash, and the issuance of 5.3 million American Depositary Shares (ADS), resulting in a $9.7 million disposal loss - The company redeemed approximately **$99.7 million** of exchangeable notes in Q1 2022[10](index=10&type=chunk)[11](index=11&type=chunk) - The redemption was funded by an **$81.3 million** senior secured term loan, existing cash, and the issuance of **5.3 million** ADS[11](index=11&type=chunk) - A **$9.7 million** loss on the disposal of exchangeable notes was recorded as a one-off charge in Q1 2022 due to the consideration under IFRS measurement being higher than the carrying value[10](index=10&type=chunk)[14](index=14&type=chunk) [New Senior Secured Term Loan Details](index=3&type=section&id=3.2%20New%20Senior%20Secured%20Term%20Loan%20Details) The company entered into an $81.3 million, 4-year senior secured term loan credit facility with Perceptive Advisors in Q1 2022, recorded on the balance sheet as a long-term liability and derivative financial balances - The company entered into an **$81.3 million**, 4-year senior secured term loan credit facility with Perceptive Advisors[16](index=16&type=chunk) - The term loan is reflected on the balance sheet as **$76.2 million** in long-term liabilities, a **$0.2 million** derivative financial asset, and a **$1.7 million** derivative financial liability, representing warrants issued to Perceptive for **2.5 million** ADS at an exercise price of **$1.30** per share[16](index=16&type=chunk) [Liquidity Position](index=4&type=section&id=3.3%20Liquidity%20Position) The company's cash balance decreased by $15.9 million to $10.0 million as of March 31, 2022, primarily due to a $9.0 million net cash outflow from debt refinancing and $3.1 million in interest payments | Metric | Dec 31, 2021 (US$m) | Mar 31, 2022 (US$m) | Change (US$m) | | :-------------------- | :---------------- | :---------------- | :---------- | | Cash balance | 25.9 | 10.0 | (15.9) | - The cash decrease was primarily due to a **$9.0 million** net cash outflow from debt refinancing (including associated fees) and **$3.1 million** in interest payments[17](index=17&type=chunk) [Consolidated Financial Statements](index=5&type=section&id=Consolidated%20Financial%20Statements) The consolidated financial statements for Q1 2022 reveal a significant revenue decline, substantial net loss, and a shift in the debt structure following the exchangeable notes redemption and new term loan [Consolidated Income Statements](index=5&type=section&id=4.1%20Consolidated%20Income%20Statements) The consolidated income statement for Q1 2022 shows a substantial revenue decrease and a significant net loss, primarily impacted by reduced clinical laboratory sales, lower gross margins, increased financial expenses, and one-off refinancing charges | (US$'000) | Three Months Ended Mar 31, 2022 | Three Months Ended Mar 31, 2021 | | :--------------------------------------- | :------------------------------ | :------------------------------ | | Revenues | 18,776 | 25,594 | | Gross profit | 7,270 | 10,913 | | Operating profit | 173 | 3,078 | | Financial expenses | (2,244) | (1,210) | | (Loss)/Profit after tax before once-off & non-cash items | (1,921) | 1,764 | | Once-off items | (10,276) | - | | (Loss)/Profit after tax | (12,279) | 1,602 | | (Loss)/ Earnings per ADS (US cents) | (50.0) | 7.7 | [Consolidated Balance Sheets](index=6&type=section&id=4.2%20Consolidated%20Balance%20Sheets) The consolidated balance sheet as of March 31, 2022, reflects a decrease in total assets, a significant reduction in current liabilities due to exchangeable notes redemption, a substantial increase in non-current liabilities from the new senior secured term loan, and an equity deficit | (US$'000) | March 31, 2022 | December 31, 2021 | | :--------------------------------------- | :--------------- | :---------------- | | TOTAL ASSETS | 106,097 | 118,895 | | Total equity/(deficit) | (6,285) | (319) | | Total current liabilities | 15,937 | 100,491 | | Total non-current liabilities | 96,445 | 18,723 | | TOTAL LIABILITIES | 112,382 | 119,214 | - The balance sheet reflects the impact of debt refinancing, with a significant reduction in exchangeable senior notes within current liabilities and the new senior secured term loan appearing in non-current liabilities[26](index=26&type=chunk) [Consolidated Statement of Cash Flows](index=7&type=section&id=4.3%20Consolidated%20Statement%20of%20Cash%20Flows) The consolidated cash flow statement for Q1 2022 shows negative free cash flow and a significant reduction in cash and cash equivalents, primarily due to net cash outflows from debt refinancing activities | (US$'000) | Three Months Ended Mar 31, 2022 | Three Months Ended Mar 31, 2021 | | :--------------------------------------- | :------------------------------ | :------------------------------ | | Cash and cash equivalents at beginning of period | 25,910 | 27,327 | | Cash generated from/(used in) operations | (1,302) | 5,893 | | Free Cash Flow | (3,798) | 3,186 | | Proceeds from term loan (net) | 80,015 | - | | Repayment of Exchangeable Notes | (86,730) | - | | Cash and cash equivalents at end of period | 10,012 | 32,277 | - Cash flows were significantly impacted by debt refinancing, with substantial cash outflows for repayment of exchangeable notes and refinancing fees, partially offset by proceeds from the term loan[28](index=28&type=chunk) [Additional Information](index=4&type=section&id=Additional%20Information) This section provides context on the use of non-IFRS financial measures, outlines the nature of forward-looking statements, and offers an overview of Trinity Biotech's business [Use of Non-IFRS Financial Measures](index=4&type=section&id=5.1%20Use%20of%20Non-IFRS%20Financial%20Measures) Trinity Biotech utilizes non-IFRS financial measures like Adjusted EBITDA and Adjusted EBITDASO to supplement IFRS consolidated financial statements for internal operational assessment and additional investor analysis - The company uses non-IFRS measures (Adjusted EBITDA, Adjusted EBITDASO) to supplement IFRS results[18](index=18&type=chunk) - These non-IFRS measures are not substitutes for IFRS but are used for internal operational assessment and to assist investors with analysis[18](index=18&type=chunk) [Forward-Looking Statements](index=4&type=section&id=5.2%20Forward-Looking%20Statements) This press release contains forward-looking statements, identified by terms such as "estimate," "project," and "expect," which are subject to known and unknown risks and uncertainties, with no obligation for the company to update or revise them - This press release contains forward-looking statements subject to known and unknown risks and uncertainties[20](index=20&type=chunk) - The company undertakes no obligation to update or revise any forward-looking statements for any reason[20](index=20&type=chunk) [About Trinity Biotech](index=4&type=section&id=5.3%20About%20Trinity%20Biotech) Trinity Biotech is a leading developer, acquirer, manufacturer, and marketer of diagnostic systems for point-of-care and clinical laboratory markets, selling products globally through direct sales and international distributors - Trinity Biotech develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory markets[21](index=21&type=chunk) - Products are used for detecting infectious diseases and quantifying hemoglobin A1c and other chemical parameters[21](index=21&type=chunk) - The company sells directly in the US, Germany, France, and the UK, and through international distributors and strategic partners in over 75 countries worldwide[21](index=21&type=chunk)

Trinity Biotech plc (NASDAQ:TRIB) Q1 2022 Earnings Conference Call June 30, 2022 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Ronan OÂ'Caoimh - Chairman and Chief Executive Officer John Gillard - Chief Financial Officer and Director Conference Call Participants Jim Sidoti - Sidoti & Co Operator Good day, and welcome to the Trinity Biotech First Quarter Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note this event is being ...

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Exhibit 99.1 Press Release dated April 11, 2022 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: investorrelations@trinitybiotech.com Trinity Biotech Announces Quarter 4 and Fiscal Year 2021 Financial Results DUBLIN, Ireland (April 11, 2022)…. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended Decembe ...

Exhibit 99.1 September 30, 2021 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: investorrelations@trinitybiotech.com Trinity Biotech Announces Results of AGM Dublin, Ireland (September 30, 2021)…. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results of the Annual General Meeting (AGM). AGM Results On September 29, 2021 Trin ...

Trinity Biotech plc (NASDAQ:TRIB) Q2 2021 Earnings Conference Call September 9, 2021 11:00 AM ET Company Participants Joe Diaz - Lytham Partners Ronan OÂ'Caoimh - Chairman and Chief Executive Officer John Gillard - Chief Financial Officer and Director Conference Call Participants Jim Sidoti - Sidoti & Co Paul Nouri - Noble Equity Funds Operator Good morning, everyone. And welcome to the Trinity Biotech Q2 2021 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instr ...

Trinity Biotech plc (NASDAQ:TRIB) Q1 2021 Results Conference Call May 25, 2021 11:00 AM ET Company Participants Joe Diaz - Lytham Partners Ronan OâCaoimh - CEO John Gillard - CFO Conference Call Participants Paul Nouri - Noble Equity Funds Jim Sidoti - Sidoti & Co Operator Good day, and welcome to the Trinity Biotech First Quarter 2021 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After todayâs presentation, there will be an opportunity to ask que ...